Biomarkers used in Alzheimer's disease diagnosis, treatment, and prevention
YAR Mahaman, KS Embaye, F Huang, L Li, F Zhu… - Ageing research …, 2022 - Elsevier
Abstract Alzheimer's disease (AD), being the number one in terms of dementia burden, is an
insidious age-related neurodegenerative disease and is presently considered a global …
insidious age-related neurodegenerative disease and is presently considered a global …
Role of oxidative damage in alzheimer's disease and neurodegeneration: From pathogenic mechanisms to biomarker discovery
FR Buccellato, M D'Anca, C Fenoglio, E Scarpini… - Antioxidants, 2021 - mdpi.com
Alzheimer's disease (AD) is a neurodegenerative disorder accounting for over 50% of all
dementia patients and representing a leading cause of death worldwide for the global …
dementia patients and representing a leading cause of death worldwide for the global …
Microglial REV-ERBα regulates inflammation and lipid droplet formation to drive tauopathy in male mice
Alzheimer's disease, the most common age-related neurodegenerative disease, is
characterized by tau aggregation and associated with disrupted circadian rhythms and …
characterized by tau aggregation and associated with disrupted circadian rhythms and …
Cholesterol metabolism in aging and age-related disorders
G Saher - Annual Review of Neuroscience, 2023 - annualreviews.org
All mammalian cell membranes contain cholesterol to maintain membrane integrity. The
transport of this hydrophobic lipid is mediated by lipoproteins. Cholesterol is especially …
transport of this hydrophobic lipid is mediated by lipoproteins. Cholesterol is especially …
Integrative metabolomics science in Alzheimer's disease: relevance and future perspectives
Alzheimer's disease (AD) is determined by various pathophysiological mechanisms starting
10–25 years before the onset of clinical symptoms. As multiple functionally interconnected …
10–25 years before the onset of clinical symptoms. As multiple functionally interconnected …
Symptomatic and disease-modifying therapy pipeline for Alzheimer's disease: Towards a personalized polypharmacology patient-centered approach
Since 1906, when Dr. Alois Alzheimer first described in a patient “a peculiar severe disease
process of the cerebral cortex”, people suffering from this pathology have been waiting for a …
process of the cerebral cortex”, people suffering from this pathology have been waiting for a …
Brain cholesterol and Alzheimer's disease: challenges and opportunities in probe and drug development
Cholesterol homeostasis is impaired in Alzheimer's disease; however, attempts to modulate
brain cholesterol biology have not translated into tangible clinical benefits for patients to …
brain cholesterol biology have not translated into tangible clinical benefits for patients to …
Status of metabolomic measurement for insights in Alzheimer's disease progression—What is missing?
Alzheimer's disease (AD) is an aging-related neurodegenerative disease, leading to the
progressive loss of memory and other cognitive functions. As there is still no cure for AD, the …
progressive loss of memory and other cognitive functions. As there is still no cure for AD, the …
Systematic review of brain and blood lipidomics in Alzheimer's disease mouse models
L Ferré-González, A Lloret, C Cháfer-Pericás - Progress in Lipid Research, 2023 - Elsevier
Alzheimer's disease (AD) diagnosis is based on invasive and expensive biomarkers.
Regarding AD pathophysiological mechanisms, there is evidence of a link between AD and …
Regarding AD pathophysiological mechanisms, there is evidence of a link between AD and …
Blood-brain barrier transporters: An overview of function, dysfunction in Alzheimer's disease and strategies for treatment
The blood-brain-barrier (BBB) has a major function in maintaining brain homeostasis by
regulating the entry of molecules from the blood to the brain. Key players in BBB function are …
regulating the entry of molecules from the blood to the brain. Key players in BBB function are …